In a New Twist in Restasis Legal Battle, Teva Sues the FDA
FAQ | Restasis® (Cyclosporine Ophthalmic Emulsion)
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents :: Pink Sheet
FDA Approvals - Big Molecule Watch | Big Molecule Watch
Court throws out Allergan's patent deal with Native American tribe - PMLiVE
Allergan settles Restasis litigation with Pfizer's InnoPharma as backlash mounts over tribal patent deal | FiercePharma
FDA Responds in Teva Pharmaceuticals Suit Alleging Unlawful Interpretation of “First Applicant” Definition under Hatch-Waxman Act | FDA Flash!
8. Restasis | FiercePharma
Allergan's Restasis Will Soon be Open to Generic Copycats After Ruling in Patent Case - Xtalks
Teva's Generic Restasis Could Punish Allergan (NYSE:AGN) | Seeking Alpha
This billion-dollar dry eye drug is behind Allergan's controversial patent deal - MarketWatch
Xiidra vs. Restasis: Differences, similarities, and which is better for you
Allergan's much-maligned tribal licensing deal wins reprieve at appeals court | FiercePharma
FDA Fires Back Over Teva Suit on Restasis 180 Days of Exclusivity | RAPS
Allergan settles Restasis patent challenge after moving patents to Native American tribe - MassDevice
US Court rejects Teva's lawsuit over generic Restasis
Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents - TheStreet
Restasis Update: Generic (Teva) available in Canada – When in the US? – Mauger Bloggers
Buy Restasis from Canada Cloud Pharmacy, the most trusted Canadian Pharmacy
7. Restasis | FiercePharma
Buy Restasis from Canada Cloud Pharmacy, the most trusted Canadian Pharmacy
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
Allergan, Inc. v. Teva Pharms.: Federal Court Invalidates Allergan Patents as Obvious - Harvard Journal of Law & Technology
